SOURCES SOUGHT
65 -- Silver Dressing Products
- Notice Date
- 3/21/2008
- Notice Type
- Sources Sought
- NAICS
- 423450
— Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- Contracting Office
- European Regional Contracting Office, ATTN:MCAA E, Building 3705, Landstuhl, Germany APO, AE 09180
- ZIP Code
- 09180
- Solicitation Number
- W9114F-08-T-9997
- Response Due
- 4/11/2008
- Archive Date
- 6/10/2008
- Point of Contact
- antonio.t.stewart, 496371868696
- E-Mail Address
-
Email your questions to European Regional Contracting Office
(antonio.stewart@amedd.army.mil)
- Small Business Set-Aside
- N/A
- Description
- 65-Medical Supplies-Potential Sources Sought --------------- A. General Information The Europe Region (TRBO Europe), a military integrated delivery network, comprised of 55 Army, Navy, and Air Force medical treatment facilities in Germany, Italy, Portugal, Spain, Turkey, United Kingdom, and Southwest Asia announces a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Silver Dressing products. This product line consists primarily of products with sizes doc umented in Phase I Technical/Company Evaluation Process of this announcement. The primary objective of this program is to standardize the quality of care across this region based on a best value determination that represents the clinically preferred product or source(s) at the best possible price. It is also intended that standardized product be obtained through the DoD Prime Vendor Program. The major facilities in the Region include but are not limited to Landstuhl Regional Medical Center, U . S. Army Hospital Heidelberg, 48th Medical Group RAF Lakenheath, 52nd Medical Group Spangdahlem, 86th Medical Group Ramstein, 39th Medical Group Incirlik, 65th Medical Group Azores, U. S. Naval Hospital Naples, U. S. Naval Hospital Rota, U. S. Army Health Center - Vicenza, U. S. Army Medical Activity Bavaria, 31st Medical Group Aviano, U. S. Naval Hospital Sigonella, U. S. Army 30th Medical Brigade, and U. S. Army CENTCOM. This standardization action is part of the Medical/Surgical Prime Vendor prog ram executed by the Defense Supply Center Philadelphia (DSCP), Directorate of Medical Materiel. In order to participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the Prime Vendors for the program. This is pursuant to the DAPA clause by which DAPA holders agree to the Standardization process and to allow Prime Vendors to distribute their items. This RFRIAQ is a supplement to the Prime Vendor Program and it is not a contract. For additional information regarding DSCPs Prime vendor program please access their web site at https://dmmonline.dscp.dla.mil The resulting Regional Incentive Agreement RIA will be for a base period of two (2) years (24 months) from date of award with three (3) 12-month option periods for a maximum of 5 years. Anticipated selection date is May 2008. The evaluation will be based on clinical, technical, and pricing factors. The Technical/Company and Clinical/Performance evaluation factors, when combined, are cons idered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become more important. The selection will be determined utilizing best value/ trade off criteria. The selection of a s ingle vendor is anticipated. However, if no single vendor can meet the total requirement of the region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of MTF preference and product availability. Point of Contact is Mrs. Marcee Whisenant, phone: 011-49-6221-172109, and e-mail marcee.whisenant@us,.army.mil B. Products & Performance Required The Europe Region is seeking product line items in the cat egory of Silver Dressings, which at a minimum includes the high volume lines below. Within this region, this product line has an estimated annual dollar requirement of $354,967.00. This forecast is based on historical prime vendor sales during a recent 12-month period. The top high volume usage line for this project is Silver Dressings in various sizes: 5x12, 1x24, 4x66, 16x16, 4x5, 4x8, 24x24, 8x16, 10x12, and 6x108. (All sizes noted above are expressed in inches unless otherwise identified.) Th e top high volume usage lines for this project are shown in the Technical/Company criteria below. At the request of the Europe Region MTFs, vendors wil l provide on-site support and in-servicing during implementation, educational resources and tools for clinical use of the product, conversion information, prime vendor order numbers, MSDS information, and itemization of the brands, types and packaging info rmation of the products supplied by the vendor. C. Instructions to Vendors DAPA holders interested in participating in this standardization initiative should email their (1) Company name and address, (2) POC (Name and Phone Number, Fax Number , and E-mail address) to marcee.whisenant@us,.army.mil. Submissions must be received by 4:00 PM EST on the specified closing date of this RFRIAQ. Vendors that fail to meet this submittal deadline will be disqualified from participation. This proce ss will include vendor requirements for providing electronic responses to technical criteria, no charge samples for clinical evaluation, and submission of electronic best price quotes. Due to the potential for e-mail to be lost in transmission from networ k security, etc., vendors are strongly encouraged to confirm with the Regional POC stated above their initial submission, quotes, and literature or other requested information has actually arrived at the Europe Regional Tri-Service Business Office (TRBO) v ia e-mail. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. D. Evaluation Criteria The Tri-Service Product Review Board (TPRB) is the governing board of the standardization process. This board includes clinicians and logisticians from the Military Treatment Facilities within the Europe Region. They are the deciding officials for this initiative. The Europe Region in tends to evaluate price quotes and select a vendor or vendors, without discussions. Vendor quotes should contain the vendors best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendors best responses to all technical and/or company questions listed in this announcement. Vendor quotes should contain the vendors best tiered-pricing discounts off of the vendors DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Region). Additionally, the Europe Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. If a down selection is made during the evaluation process, the Europe Region may limit the number of quotes to the greatest number that will permit an efficient competition among vendors. Phase I Technical/Company Evaluation Process: Interested vendors will respond to this FBO announcement by emailing their intent to participate to th e above POC by the required response date. Based on vendor responses, the TRBO POC will request detailed responses to the technical/company criteria from each vendor. Vendors are required to meet/provide responses to the technical/company criteria stated below. All technical/company criteria are weighted equally. The responses will be reviewed under the purview of the TPRB and the Clinical Product Team (CPT) to determine acceptability. After review of the technical/company criteria, those vendors who meet these criteria will be qualified/invited to participate in the clinical/performance evaluation. Acceptability for purposes of evaluation of technical/company criteria: Generally, responses to all questions in this section demonstrate: (1) the business concern submitting the quote is a distributor or manufacturer of a complete line of the subject medical/surgical consumables; (2) based on the vendors responses, the evaluators have reasonable confidence that the line or products and/or services submitted meet the medical standards of care of the community, applicable to such products or services; (3) the vendor has or is obtaining a DAPA for the items (vendors that fail to have a DAPA will be disqualified); (4) the vendor has, or is obtaining, an agreement covering the items with Owens & Minor, the Prime Vendor (PV) for the region (vendors whose products are not available through the regional PV will b e disqualified); (5) the vendor intends to provide discounts off DAPA for all products included in this standardization initiative (vendors that fail to provide a discount from DAPA will be disqualified); and (6) the vendors information provided is factua lly correct. Any misrepresentation of information will disqualify the vendor from further consideration. The following Technical/Company Evaluation Criteria have been established for the standardization initiative: 1. At a minimum your compa ny must manufacture or distribute Silver Dressings in the following sizes: 5x12, 1x24, 4x66, 16x16, 4x5, 4x8, 24x24, 8x16, 10x12, and 6x108. All sizes are expressed in inches unless otherwise identified. 2. Vendors must have a DAPA or be in the proce ss of applying for a DAPA number for the Silver Dressing product line. Provide the DAPA number or proof of the application process with the initial submittal. (Note that vendors that fail to have a DAPA or show a lack of progress in obtaining a DAPA will be disqualified.) Your DAPA number is: __________________. 3. Vendors must have a separate agreement with the PV (currently, Europes PV is Owens & Minor) for distribution in the Europe Region. (Note that vendors whose products are not available thr ough the regional PV will be disqualified.) 4. Vendors must offer discounts off DAPA for all products included in this standardization initiative. (Note that vendors that fail to offer a discount from DAPA will be disqualified.) 5. Vendors must pro vide electronic and hard copy proposed pricing and a competitive product cross-reference in electronic Microsoft Excel format upon request. 6. Your company must be able to send samples to this region by United States Postal Service (USPS). This form of mailing has proven to be the best at eliminating delays due to International Customs. 7. Vendor must be able to ship samples necessary for evaluation via United States Parcel Service eliminating delays that occur with Europes Custom Offices. Provi de acknowledgement of this requirement with the initial submittal. 8. Vendors must provide any history of back orders and/or recalls that occurred during the most recent 24-month period for their Silver Dressing products including dates, duration, cause , and resolution with their initial submittals. Your company must provide history of back orders and/or recalls for the Silver Dressing products, which will include: dates, duration, cause, and resolution (WITH INITIAL SUBMITTAL). 9. For any Silver Dre ssing products containing medication, vendors must provide products with FDA approval for use in all clinical advanced wound care settings and provide literature to support this requirement (WITH INITIAL SUBMITTAL). 10. Vendors must provide a statement revealing all products containing synthesized polymer (plastic/rubber) clearly labeled as latex free/safe. 11. Vendors must supply a statement demonstrating instructions/directions for use with each unit of issue and provide evidence of this with thei r initial submittals. 12. Vendors must provide a statement confirming evidence that products can be delivered to a sterile field with (WITH INITIAL SUBMITTAL). 13. Your company is required to provide literature support showing the mechanism that ensu res normal bacteria of the wound and the promotion of wound healing. 14. Vendors must provide visual examples demonstrating product labels with visible expiration dates of at least 12 pt fonts on all exterior, intermediate and individual packaging and p rovide evidence of such (WITH INITIAL SUBMITTAL). Phase II Clinical/Performance Evaluation Process: The multi-disciplinary CPT formed by the TPRB will r equest literature and/or samples (no charge) from the product line to be clinically evaluated at select Military Treatment facilities. The CPT will evaluate the product line using both a literature review and hands on evaluation in a non-clinical setting. As indicated in the technical/company criteria above, vendors are required to ship samples to the Europe Tri-Service Regional Business Office (TRBO) via United States Parcel Service (USPS) to the following APO address: Commander, Europe Regional Medic al Command Attn: G-4 TriService Standardization Mr. Rob Halliday, (DSN 371-2108) CMR 442 APO AE 09042 Literature will be e-mailed or shipped via the same procedure as samples. Vendors will be given 10 calendar days to ship samples. Literat ure and samples must be shipped to the TRBO by COB, 4:00PM EST on the 10th calendar day after the notice to ship. Vendors failing to ship by the deadline will be disqualified from further consideration in the standardization process. Vendors must forward verification (e-mail) of shipment to the TRBO. Designated MTFs will evaluate the clinical/performance criteria using a Likert scale, with a one to five rating. One (1) is equal to not acceptable, two (2) is equal to minimally acceptable, three (3) is equal to acceptable, four (4) is equal to most acceptable, and five (5) is equal to highly acceptable. All clinical/performance criteria are weighted equally. The CPT has established a target threshold of 3.00 for the clinically acceptability of produc ts for standardization. The CPT will analyze this acceptability as being at or near 3.00 depending on the break in the average scores and how closely scores are clustered near the Acceptability Target Threshold of 3.00. Subject to this review, products b elow this threshold will be clinically unacceptable and will be disqualified from further consideration for standardization. To determine acceptability, a CPT comprised of medical professionals from multiple disciplines will evaluate the product s based on the evaluation criteria below. The CPT intends clinical evaluations be conducted in a non-clinical setting; however, the Government reserves the right to conduct evaluations in an inpatient setting, if needed. The following Clinical/Perf ormance Evaluation Criteria have been established for this standardization initiative: Clinical Acceptability Target Threshold: 3.00 Silver Dressings: 1. Dressing may be cut to required size. 2. Dressing does not cause a local advers e reaction. 3. Skin remains intact when dressing is removed. 4. The literature displays the requirement that the dressing is an effective barrier against a wide range of microbes. Market Search Request for Information: Our clinicians are atte mpting to stay abreast of technological advances in this product line. None of the information provided based on the following feedback will be used to determine technical or clinical acceptability. Please describe any features that your products possess that use new design or technology. Phase III Pricing Analysis Process: After the clinical/performance evaluations is completed and analyzed, all vendors in the clinical evaluation group who met the minimum 3.00 clinical threshold (depending on the break in the average scores and how closely scores are clustered near the Acceptability Target Threshold as determined by the CPT) will be contacted to submit their lowest pricing quotes as well as product cross-reference data based on a committed volume of 80% of the total Europe Regional requirement. Vendors will be provided ten (10) calendar days to submit their price quotes in the prescribed format as above via email. Price quotes must be received by 4:00 PM EST on the 10th calendar day. Failure t o respond within this timeframe or failure to submit incentive discounts from their DAPA prices will result in the vendor being disqualified from further partic ipation in this RIA initiative. The Europe Region intends to evaluate quotes and select a vendor or vendors, without discussions as noted above. However, the Europe Region reserves the right to conduct discussions and request revised pricing, if determine d to be necessary. Clinical/performance and technical/company factors will be weighted more heavily than price. As the technical and clinical evaluation results become more equal, price will become more important. Pricing will be evaluated based o n best value to the government and will be based on a committed volume for a two year period with possible one-year option periods (not to exceed 5 years). The following elements will be considered in the pricing analysis: 1) Impact of RIA prices on the Europe Region (Post-Standardization Costs), 2) Potential Cost Avoidance, 3) Impact of unmatched lines, and 4) Consideration of stock keeping units (SKUs) by each vendor. Due to the potential for Base DAPA prices to be inflated, the Impact of RIA prices on the Europe Region is considered more important than other pricing elements.
- Place of Performance
- Address: European Regional Contracting Office ATTN:MCAA E, Building 3705 Landstuhl, Germany APO AE
- Zip Code: 09180
- Country: GE
- Zip Code: 09180
- Record
- SN01538800-W 20080323/080321224635 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |